Oxford Biomedica plc (LON:OXB) Insider Heather Preston Buys 11,389 Shares

Oxford Biomedica plc (LON:OXB) insider Heather Preston acquired 11,389 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were bought at an average price of GBX 324 ($4.36) per share, with a total value of £36,900.36 ($49,690.76).

Oxford Biomedica Trading Down 0.2%

Shares of OXB stock opened at GBX 313.50 ($4.22) on Friday. The stock has a market cap of £333.25 million, a price-to-earnings ratio of -2.33 and a beta of 1.09. Oxford Biomedica plc has a 1-year low of GBX 232.50 ($3.13) and a 1-year high of GBX 455 ($6.13). The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The stock has a 50-day moving average of GBX 308.28 and a 200-day moving average of GBX 347.05.

Oxford Biomedica (LON:OXB) last posted its quarterly earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.56)) EPS for the quarter. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%. On average, equities research analysts forecast that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.